(Q41902763)

13 October 2017

Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. (English)

1 reference

13 October 2017

M Achira

1

1 reference

13 October 2017

H Suzuki

series ordinal

2

1 reference

13 October 2017

K Ito

series ordinal

3

1 reference

13 October 2017

Y Sugiyama

series ordinal

4

1 reference

13 October 2017

1 January 1999

1 reference

13 October 2017

1 reference

13 October 2017

1

1 reference

13 October 2017

4

1 reference

13 October 2017

E18

1 reference

Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

First-pass metabolism of midazolam by the human intestine.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine*

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751348

First-pass metabolism of cyclosporin by the gut

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11741214

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11741214

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1208/PS010418

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

11741214

1 reference